中文

Journal of Shanghai University >

2018 , Vol. 24 >Issue 6: 853 - 860

DOI: https://doi.org/10.12066/j.issn.1007-2861.2096

Research Paper

Effectiveness of activation of sigma-1 receptor on reducing myocardium injury in ischemia reperfusion

Expand
  • 1. Department of Cardiology, Anting Hospital, Shanghai 201805, China
    2. Department of Cardiology, Tongji Hospital Affiliated to Tongji University, Shanghai 200065, China

Received date: 2018-06-22

  Online published: 2018-12-24

Fold

Abstract

[Objective] This paper attempts to investigate whether sigma-1 receptor (Sig1R) activation attenuate myocardial ischemia reperfusion injury (MIRI) and whether Sig1R inhibition exacerbates MIRI in mice model. [Methods] C57BL/6 mice are injected via tail vein with BD1047 (Sig1R inhibitor), SA4503 (Sig1R activator) or saline 3 days before MIRI surgery. Then, double-staining technique and western blot analysis are performed on myocardium tissue. [Results] Mice that have received BD1047 pretreatment demonstrate a significant increase in the myocardial infarction size after I/R compared with control group ($P\!\!<$0.05), and a significantly increased expression of Bax and Caspases-3 proteins and a significantly reduced expression of Bcl-2 protein compared with sham control, MIRI control and sham BD1047 groups ($P\!<$0.05). Mice that have received SA4503 pretreatment demonstrate a significant reduction in myocardial infarction size after I/R compared with control group ($P\!<$0.05), and a significantly reduced expression of Bax and cleaved Caspases-3 proteins and a significantly increased expression of Bcl-2 protein compared with sham control, MIRI control and sham SA4503 groups ($P\!<$0.05). [Conclusions] SA4503 protects MIRI and reduces myocardial infarction whereas BD1047 deteriorates MIRI and augment myocardial infarction, and these effects may be achieved through activation or inhibition of Sig1R.

Key words： Sigma-1 receptor; mycardial infarction; ischemia reperfusion injury

Cite this article

LIAO Xiaoping, YU Pujiao, XU Jiahong . Effectiveness of activation of sigma-1 receptor on reducing myocardium injury in ischemia reperfusion[J]. Journal of Shanghai University, 2018 , 24(6) : 853 -860 . DOI: 10.12066/j.issn.1007-2861.2096

References

[1] Yellon D M, Hausenloy D J. Myocardial reperfusion injury[J]. N Engl J Med, 2007,357:1121-1135.
[2] Hausenloy D J, Yellon D M. Targeting myocardial reperfusion injury: the search continues[J]. N Engl J Med, 2015,373:1073-1075.
[3] Hausenloy D J, Yellon D M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target[J]. J Clin Invest, 2013,123:92-100.
[4] Ibá?ez B, Heusch G, Ovize M, et al. Evolving therapies for myocardial ischemia/reperfusion injury[J]. J Am Coll Cardiol, 2015,65:1454-1471.
[5] Lejay A, Fang F, John R, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus[J]. Journal of Molecular and Cellular Cardiology, 2016,91:11-22.
[6] Hayashi T, Su T P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival [J]. Cell, 2007,131:596-610.
[7] Su T P, Hayashi T, Maurice T, et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator[J]. Trends Pharmacol Sci, 2010,31:557-566.
[8] Fujimoto M, Hayashi T, Urfer R, et al. Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor[J]. Synapse, 2012,66:630-639.
[9] Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of NF$\kappa$B[J]. J Pharmacol Exp Ther, 2010,332:388-397.
[10] Tsai S Y, Hayashi T, Mori T, et al. Sigma-1 receptor chaperones and diseases[J]. Cent Nerv Syst Agents Med Chem, 2009,9:184-189.
[11] Klouz A, Sa?d D B, Ferchichi H, et al. Protection of cellular and mitochondrial functions against liver ischemia by $N$-benzyl-$N$'-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand[J]. Eur J Pharmacol, 2008,578(2/3):292-299.
[12] Hosszu A, Antal Z, Lenart L, et al. $\sigma $1-receptor agonism protects against renal ischemia-reperfusion injury[J]. J Am Soc Nephrol, 2017,28(1):152-165.
[13] Bucolo C, Drago F. Neuroactive steroids protect retinal tissue through $\sigma $1 receptors[J]. Basic Clin Pharmacol Toxicol, 2007,100:214-216.
[14] Shen Y C, Wang Y H, Chou Y C, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation[J]. J Neurochem, 2008,104:558-572.
[15] Tagashira H, Zhang C, Lu Y M, et al. Stimulation of $\sigma $1-receptor restores abnormal mitochondrial Ca2+ mobilization and ATP production following cardiac hypertrophy [J]. Biochim Biophys Acta, 2013,1830:3082-3094.
[16] Tagashira H, Bhuiyan M S, Shioda N, et al. Fluvoxamine rescues mitochondrial Ca2+ transport and ATP production through $\sigma $1-receptor in hypertrophic cardiomyocytes [J]. Life Sci, 2014,95:89-100.
[17] Bhuiyan M S, Fukunaga K. Stimulation of sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats[J]. Expert Opin Ther Targets, 2009,13:1253-1265.
[18] Bhuiyan M S, Tagashira H, Fukunaga K. Dehydroepiandrosterone mediated stimulation of sigma-1 receptor activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding[J]. Cardiovasc Ther, 2010,29:219-230.
[19] Bhuiyan M S, Tagashira H, Fukunaga K. Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding[J]. Eur J Pharmacol, 2011,650:621-628.
[20] Ito K, Hirooka Y, Matsukawa R, et al. Decreased brain sigma-1 receptor contributes to the relationship between heart failure and depression[J]. Cardiovas Res, 2012,93:33-40.
[21] Dumont E A, Hofstra L, Van Heerde W L, et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-Ⅴ in a mouse model[J]. Circulation, 2000,102:1564-1568.
[22] Dumont E A, Reutelingsperger C P, Smits J F, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart[J]. Nature Medicine, 2001,7(12):1352-1355.
[23] Whelan R S, Kaplinskiy V, Kitsis R N. Cell death in the pathogenesis of heart disease: mechanisms and significance[J]. Annu Rev Physiol, 2010,72:19-44.
[24] Hausenloy D J, Yellon D M. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion[J]. J Mol Cell Cardiol, 2003,35:339-341.
[25] Ong S B, Samangouei P, Kalkhoran S B, et al. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury[J]. J Mol Cell Cardiol, 2015,78:23-34.
[26] Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium[J]. Circ Res, 1996,79:949-956.
[27] Di Lisa F, Canton M, Menabo R, et al. Mitochondria and reperfusion injury: the role of permeability transition[J]. Basic Res Cardiol, 2003,98:235-241.
[28] Halestrap A P, Richardson A P. The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury[J]. J Mol Cell Cardiol, 2015,78:129-141.
[29] Eltzschig H K, Eckle T. Ischemia and reperfusion: from mechanism to translation[J]. Nat Med, 2011,17:1391-1401.
[30] Shimazawa M, Sugitani S, Inoue Y, et al. Effect of a sigma-1 receptor agonist, cutamesine dihydrochloride (SA4503), on photoreceptor cell death against light-induced damage[J]. Exp Eye Res, 2015,132:64-72.
[31] Urfer R, Moebius H J, Skoloudik D, et al. Cutamesine stroke recovery study group. Phase Ⅱ trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke[J]. Stroke, 2014,45:3304-3310.
Options
Outlines

/

〈 〉